Tenaya insider plans sale of 1,408,910 shares

A Tenaya Therapeutics stockholder filed a notice of proposed sale of 1,408,910 common shares under Rule 144.

Rhea-AI Filing Summary

A Tenaya Therapeutics stockholder filed a notice of proposed sale of 1,408,910 common shares under Rule 144. The shares have an aggregate market value of $1,113,038.00, with an approximate sale date of February 10, 2026 on the NASDAQ exchange.

The seller previously acquired these common shares in Series A financing transactions from Tenaya Therapeutics on October 13, 2016 and July 31, 2017, paying the purchase price in cash. The person signing the notice represents that they are not aware of undisclosed material adverse information about Tenaya’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TNYA disclose?

The Form 144 for TNYA discloses a stockholder’s intention to sell 1,408,910 common shares of Tenaya Therapeutics under Rule 144. It outlines share quantity, market value, acquisition details, planned sale date, and trading venue.

How many Tenaya Therapeutics (TNYA) shares are planned for sale?

The filing states that 1,408,910 common shares of Tenaya Therapeutics are proposed to be sold. These shares relate to a previously acquired position and represent a specific block the stockholder intends to sell under Rule 144 conditions.

What is the aggregate market value of the TNYA shares to be sold?

The proposed sale of Tenaya Therapeutics shares has an aggregate market value of $1,113,038.00. This value reflects the filer’s calculation for the 1,408,910 common shares covered by the notice at the time of preparing the Form 144.

When might the Tenaya Therapeutics (TNYA) Rule 144 sale occur?

The notice lists an approximate sale date of February 10, 2026. This date indicates when the stockholder expects to begin selling the 1,408,910 Tenaya Therapeutics common shares described in the Form 144 on the NASDAQ exchange.

How were the TNYA shares in this Form 144 originally acquired?

The shares were acquired in Series A financing transactions from Tenaya Therapeutics on October 13, 2016 and July 31, 2017. The Form 144 notes that the purchase price for these common shares was paid entirely in cash.

On which exchange will the Tenaya Therapeutics (TNYA) shares be sold?

The Form 144 indicates that the NASDAQ exchange is the trading venue for the planned sale. The 1,408,910 Tenaya Therapeutics common shares are expected to be sold through a broker, BTIG, LLC, in transactions executed on NASDAQ.

What representation does the seller make in the TNYA Form 144?

The person for whose account the securities will be sold represents that they do not know any undisclosed material adverse information about Tenaya Therapeutics’ current or prospective operations at the time of signing the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 05:06 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001668159
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tenaya Therapeutics, Inc.
SEC File Number	001-40656
Address of Issuer	171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	415-865-2066
Name of Person for Whose Account the Securities are To Be Sold	COLUMN GROUP III, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	1408910	1113038.00	213744535	02/10/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/13/2016	Series A financing	Tenaya Therapeutics			25438	10/13/2016	Cash
Common	10/13/2016	Series A financing	Tenaya Therapeutics			747042	10/13/2016	Cash
Common	07/31/2017	Series A financing	Tenaya Therapeutics			636430	07/31/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Evangelista
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)